Basal values and changes of liver stiffness predict the risk of disease progression in compensated advanced chronic liver disease

Mònica Pons, Macarena Simón-Talero, Laura Millán, Meritxell Ventura-Cots, Begoña Santos, Salvador Augustin, Joan Genescà

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

20 Cites (Scopus)

Resum

© 2016 Editrice Gastroenterologica Italiana S.r.l. Background and aims Transient elastography has been proposed as a tool to predict the risk of decompensation in patients with chronic liver disease. We aimed to identify risk groups of disease progression, using a combination of baseline liver stiffness measurement (LSM) and its change over time (delta-LSM) in patients with compensated advanced chronic liver disease (cACLD). Methods Ninety-four patients with baseline LSM ≥10 kPa, Child–Pugh score 5 and without previous decompensation were included. A second LSM was performed during follow-up and data on liver function and liver-related events were collected. The primary endpoint was a composite that included death, liver decompensation and impairment in at least 1 point in Child–Pugh score. Results After a median follow-up of 43.6 months, 15% of patients presented the primary endpoint. Multivariate analysis identified baseline LSM (OR 1.12, P = 0.002) and delta-LSM (OR 1.02, P = 0.048) as independent predictors of the primary endpoint. A high risk group represented by patients with baseline LSM ≥21 kPa and delta-LSM ≥10% (risk of progression 47.1%, 95% CI: 23–71%) was identified, while patients with LSM <21 kPa and delta-LSM <10% presented zero risk of progression (P = 0.03). Conclusions Simple classification rules using baseline LSM and delta-LSM identify cACLD patients at low or high risk of disease progression.
Idioma originalAnglès
Pàgines (de-a)1214-1219
RevistaDigestive and Liver Disease
Volum48
Número10
DOIs
Estat de la publicacióPublicada - 1 d’oct. 2016

Fingerprint

Navegar pels temes de recerca de 'Basal values and changes of liver stiffness predict the risk of disease progression in compensated advanced chronic liver disease'. Junts formen un fingerprint únic.

Com citar-ho